Why the study?
Does andexanet alfa improve hemostatic efficacy in patients with acute major bleeding associated with the use of a factor Xa inhibitor?
Does andexanet alfa improve hemostatic efficacy in patients with acute major bleeding associated with the use of a factor Xa inhibitor?
Andexanet alfa effectively reduces anti-factor Xa activity and provides excellent or good hemostatic efficacy in patients with acute major bleeding on factor Xa inhibitors.
May support andexanet use in factor Xa bleeding; leaves open need for randomized outcome confirmation.
In patients with acute major bleeding associated with the use of a factor Xa inhibitor, treatment with andexanet markedly reduced anti-factor Xa activity, and 82% of patients had excellent or good hemostatic efficacy at 12 hours, as adjudicated according to prespecified criteria. (Funded by Portola Pharmaceuticals; ANNEXA-4 ClinicalTrials.gov number, NCT02329327.).
No takes yet. Share an insight, caveat, or question.
Connolly et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: